Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection

被引：12

作者：

Mensa, Federico J. ^{[1
]}

Lovell, Sandra ^{[2
]}

Pilot-Matias, Tami ^{[3
]}

Liu, Wei ^{[4
]}

机构：

[1] AbbVie Inc, Dept Clin Dev Infect Dis, N Chicago, IL 60064 USA

[2] AbbVie Inc, Dept Stat, N Chicago, IL 60064 USA

[3] AbbVie Inc, Dept Clin Virol, N Chicago, IL 60064 USA

[4] AbbVie Inc, Dept Pharmacokinet, N Chicago, IL 60064 USA

来源：

FUTURE MICROBIOLOGY | 2019年 / 14卷 / 02期

关键词：

chronic HCV infection; chronic kidney disease; cirrhosis; glecaprevir; HCV; hepatitis C virus; HIV; NS3; 4A protease inhibitor; NS5A inhibitor; pibrentasvir; HCV GENOTYPE 1; COMPENSATED CIRRHOSIS; RESISTANCE ANALYSIS; NEXT-GENERATION; SAFETY; EFFICACY; PIBRENTASVIR; PHARMACOKINETICS; GLECAPREVIR; ADULTS;

D O I：

10.2217/fmb-2018-0233

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

In recent years, management of chronic hepatitis C virus (HCV) infection has been revolutionized by the availability of oral direct-acting antivirals (DAAs), which have significantly better efficacy and safety profiles than interferon-containing regimens. Simple, short-duration DAA therapies will facilitate expansion of HCV treatment to nonspecialist providers, which will be vital to achieve the WHO target of eliminating chronic HCV as a major public health threat by 2030. Coformulated glecaprevir/pibrentasvir is the only 8-week, pan-genotypic, 2-DAA regimen recommended by international guidelines as a first-line regimen in treatment-naive, noncirrhotic HCV genotype 1-6 patients. This review provides a comprehensive summary of the pharmacodynamic and pharmacokinetic parameters, efficacy, safety and place in the HCV treatment paradigm for glecaprevir/pibrentasvir.

引用

页码：89 / 110

页数：22

共 69 条

[21] Liver Fibrosis Progression in Hepatitis C Virus Infection After Seroconversion [J].

Butt, Adeel A. ;

Yan, Peng ;

Lo Re, Vincent, III ;

Rimland, David ;

Goetz, Matthew B. ;

Leaf, David ;

Freiberg, Matthew S. ;

Klein, Marina B. ;

Justice, Amy C. ;

Sherman, Kenneth E. .

JAMA INTERNAL MEDICINE, 2015, 175 (02) :178-185

[22] Significant changes of HCV patient characteristics over time in the era of direct antiviral agent therapy - are all HCV subpopulations treated similarly? - Results from the German hepatitis C Cohort [J].

Christensen, S. ;

Ingiliz, P. ;

Zur Wiesch, J. Schulze ;

Schewe, K. ;

Boesecke, C. ;

Hueppe, D. ;

Baumgarten, A. ;

Thomas, L. ;

Schmutz, G. ;

Georg, S. K. ;

Florian, B. ;

Heiner, B. ;

Mauss, S. .

JOURNAL OF HEPATOLOGY, 2018, 68 :S289-S290

[23] Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study [J].

D'Ambrosio, R. ;

Pasulo, L. ;

Puoti, M. ;

Schiavini, M. ;

Vigano, P. ;

Vinci, M. ;

Menzaghi, B. ;

Zuin, M. G. ;

Soria, A. ;

Spinetti, A. ;

Aghemo, A. ;

Rumi, M. G. ;

Uberti-Foppa, C. ;

Pan, A. ;

Spinelli, O. ;

Monforte, A. D'arminio ;

Capretti, A. ;

Colli, A. ;

Colombo, A. ;

Spinzi, G. ;

Centenaro, R. ;

Buscarini, E. ;

Soffredini, R. ;

Borghi, M. ;

Colpani, M. ;

Lazzaroni, S. ;

Maggiolo, F. ;

Gori, A. ;

Del Poggio, P. ;

Giorgini, A. ;

Morini, L. ;

Pigozzi, M. G. ;

Dibenedetto, C. ;

Giglio, O. ;

Magni, C. F. ;

Noventa, F. ;

Lampertico, P. ;

Fagiuoli, S. .

JOURNAL OF HEPATOLOGY, 2018, 68 :S65-S65

[24] Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir" [J].

Dore, Gregory J. ;

Feld, Jordan J. .

CLINICAL INFECTIOUS DISEASES, 2015, 60 (12) :1829-1836

[25] Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis C virus infection: an integrated analysis [J].

Dufour, J. -F. ;

Zuckerman, E. ;

Zadeikis, N. ;

Hezode, C. ;

Paik, S. W. ;

Andreone, P. ;

Weiland, O. ;

Slim, J. ;

Flamm, S. L. ;

Morgan, T. ;

Vargas, H. ;

Strasser, S. ;

Brown, A. ;

Yu, Y. ;

Porcalla, A. ;

Mensa, F. .

JOURNAL OF HEPATOLOGY, 2017, 66 (01) :S515-S515

[26] EASL Recommendations on Treatment of Hepatitis C 2018 [J].

Pawlotsky J.-M. ;

Negro F. ;

Aghemo A. ;

Berenguer M. ;

Dalgard O. ;

Dusheiko G. ;

Marra F. ;

Puoti M. ;

Wedemeyer H. .

JOURNAL OF HEPATOLOGY, 2018, 69 (02) :461-511

[27] Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection [J].

Feld, J. J. ;

Jacobson, I. M. ;

Hezode, C. ;

Asselah, T. ;

Ruane, P. J. ;

Gruener, N. ;

Abergel, A. ;

Mangia, A. ;

Lai, C. -L. ;

Chan, H. L. Y. ;

Mazzotta, F. ;

Moreno, C. ;

Yoshida, E. ;

Shafran, S. D. ;

Towner, W. J. ;

Tran, T. T. ;

McNally, J. ;

Osinusi, A. ;

Svarovskaia, E. ;

Zhu, Y. ;

Brainard, D. M. ;

McHutchison, J. G. ;

Agarwal, K. ;

Zeuzem, S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) :2599-2607

[28]

Flamm SL, 2017, HEPATOLOGY, V66, p35A

[29] Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial [J].

Forns, Xavier ;

Lee, Samuel S. ;

Valdes, Joaquin ;

Lens, Sabela ;

Ghalib, Reem ;

Aguilar, Humberto ;

Felizarta, Franco ;

Hassanein, Tarek ;

Hinrichsen, Holger ;

Rincon, Diego ;

Morillas, Rosa ;

Zeuzem, Stefan ;

Horsmans, Yves ;

Nelson, David R. ;

Yu, Yao ;

Krishnan, Preethi ;

Lin, Chih-Wei ;

Kort, Jens J. ;

Mensa, Federico J. .

LANCET INFECTIOUS DISEASES, 2017, 17 (10) :1062-1068

[30] Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection [J].

Foster, G. R. ;

Afdhal, N. ;

Roberts, S. K. ;

Braeu, N. ;

Gane, E. J. ;

Pianko, S. ;

Lawitz, E. ;

Thompson, A. ;

Shiffman, M. L. ;

Cooper, C. ;

Towner, W. J. ;

Conway, B. ;

Ruane, P. ;

Bourliere, M. ;

Asselah, T. ;

Berg, T. ;

Zeuzem, S. ;

Rosenberg, W. ;

Agarwal, K. ;

Stedman, C. A. M. ;

Mo, H. ;

Dvory-Sobol, H. ;

Han, L. ;

Wang, J. ;

McNally, J. ;

Osinusi, A. ;

Brainard, D. M. ;

McHutchison, J. G. ;

Mazzotta, F. ;

Tran, T. T. ;

Gordon, S. C. ;

Patel, K. ;

Reau, N. ;

Mangia, A. ;

Sulkowski, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) :2608-2617

← 1 2 3 4 5 6 7 →